NASDAQ : NAMS
NewAmsterdam Pharma Company N.V. — Key statistics
Healthcare · Biotechnology · Netherlands
Last price 20.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.48B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.40B |
| Enterprise Value | 1.72B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 119.54M |
| Shares Outstanding | 119.54M |
| Shares Change (YoY) | +12.87% |
| Shares Change (QoQ) | +1.36% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 75.16% |
| Float | 81.50M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 336.74 |
| Forward PS | 85.03 |
| PB Ratio | 3.74 |
| P/TBV Ratio | 3.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 241.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.03 |
| Quick Ratio | 8.76 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -36.81% |
| Return on Assets (ROA) | -20.11% |
| Return on Invested Capital (ROIC) | -21.66% |
| Return on Capital Employed (ROCE) | -38.70% |
| Weighted Average Cost of Capital (WACC) | 4.80% |
| Revenue Per Employee | $71,210 |
| Profits Per Employee | -$2.60M |
| Employee Count | 100 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.10 |
| 52-Week Price Change | -44.02% |
| 50-Day Moving Average | 22.86 |
| 200-Day Moving Average | 29.80 |
| Relative Strength Index (RSI) | 40.70 |
| Average Volume (20 Days) | 1,389,831 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 14.11M |
| Short Previous Month | 19.05M |
| Short % of Shares Out | 13.81% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.28 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 7.12M |
| Gross Profit | 7.12M |
| Operating Income | -244.41M |
| Pretax Income | -259.50M |
| Net Income | -259.50M |
| EBITDA | -244.16M |
| EBIT | -244.41M |
| Loss Per Share | -$2.14 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 633.85M |
| Total Debt | 82,000 |
| Net Cash | 678.18M |
| Net Cash Per Share | $5.67 |
| Equity (Book Value) | 631.42M |
| Book Value Per Share | 5.37 |
| Working Capital | 586.23M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -143.46M |
| Capital Expenditures | -260,000 |
| Depreciation & Amortization | 244,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -143.72M |
| FCF Per Share | -$1.20 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -3,432.20% |
| Pretax Margin | -3,644.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.87% |
| Shareholder Yield | -12.87% |
| Earnings Yield | -10.69% |
| FCF Yield | -5.99% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $49.96 |
| Price Target Difference | 149.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 152.83% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 27.61 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |